Pasireotide Can Induce Sustained Decreases in Urinary Cortisol and Provide Clinical Benefit in Patients with Cushing’s Disease: Results from an Open-Ended, Open-Label Extension Trial
AuthID
P-00R-0K0
P-00R-0K0